Ad
related to: fixed drug reaction treatment program
Search results
Results from the WOW.Com Content Network
Fixed drug reactions are common and so named because they recur at the same site with each exposure to a particular medication. [1] Medications inducing fixed drug eruptions are usually those taken intermittently.
Generalized bullous fixed drug eruption (GBFDE) most commonly refers to a drug reaction in the erythema multiforme group. [3]: 129 These are uncommon reactions to medications, with an incidence of 0.4 to 1.2 per million person-years for toxic epidermal necrolysis and 1.2 to 6.0 per million person-years for Stevens–Johnson syndrome.
A fixed drug eruption is the term for a drug eruption that occurs in the same skin area every time the person is exposed to the drug. Eruptions can occur frequently with a certain drug (for example, with phenytoin [ 8 ] ), or be very rare (for example, Sweet's syndrome following the administration of colony-stimulating factors [ 9 ] ).
White explained in an email that his reaction to Hazelden’s plan was “one of pleasant surprise that a leading addiction treatment program would so value the emerging addiction science and be so committed to improving recovery outcomes that it would be willing to weather potential controversy that could affect its business interests.”
Barriers to accessing drug treatment may worsen negative health outcomes and further exacerbate health inequalities in the United States. Stigmatization of drug use, the War on Drugs and criminalization, and the social determinants of health should all be considered when discussing access to drug treatment and potential barriers.
Type A: augmented pharmacological effects, which are dose-dependent and predictable [5]; Type A reactions, which constitute approximately 80% of adverse drug reactions, are usually a consequence of the drug's primary pharmacological effect (e.g., bleeding when using the anticoagulant warfarin) or a low therapeutic index of the drug (e.g., nausea from digoxin), and they are therefore predictable.
The risk of first-degree relatives developing the same hypersensitivity reaction is higher than in the general population. [ 1 ] As this syndrome can present secondary to multiple anticonvulsants, the general term "anticonvulsant hypersensitivity syndrome" (AHS) is favored over the original descriptive term "dilantin hypersensitivity syndrome."
A drug-therapy (related) problem can be defined as an event or circumstance involving drug treatment (pharmacotherapy) that interferes with the optimal provision of medical care. In 1990, L.M. Strand and her colleagues (based on the previous work of R.L Mikeal [ 3 ] and D.C Brodie, [ 4 ] published respectively in 1975 and 1980) classified the ...
Ad
related to: fixed drug reaction treatment program